Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Supply, Demand and Key Producers, 2023-2029

Page: 105

Published Date: 07 Aug 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size is expected to reach $ 16370 million by 2029, rising at a market growth of 28.1% CAGR during the forecast period (2023-2029).

The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patient's T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients.

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.

This report studies the global Chimeric Antigen Receptor (CAR) T-Cell Therapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Chimeric Antigen Receptor (CAR) T-Cell Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Chimeric Antigen Receptor (CAR) T-Cell Therapy that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy total market, 2018-2029, (USD Million)
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Chimeric Antigen Receptor (CAR) T-Cell Therapy total market, key domestic companies and share, (USD Million)
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy revenue by player and market share 2018-2023, (USD Million)
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy total market by Type, CAGR, 2018-2029, (USD Million)
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics, Autolus Therapeutics and Sorrento Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Chimeric Antigen Receptor (CAR) T-Cell Therapy market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, Segmentation by Type
    CD19-targeted
    BCMA-targeted

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, Segmentation by Application
    Lymphoma
    Multiple Myeloma

Companies Profiled:
    Novartis
    Gilead Sciences
    Bristol-Myers Squibb
    J & J
    JW Therapeutics
    FOSUNKite
    CARsgen Therapeutics
    Autolus Therapeutics
    Sorrento Therapeutics
    Mustang Bio
    Bluebird Bio
    Cellectis
    Allogene Therapeutics
    Celyad

Key Questions Answered
1. How big is the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market?
2. What is the demand of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market?
3. What is the year over year growth of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market?
4. What is the total value of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market?
5. Who are the major players in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Introduction
    1.2 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Total Market by Region (by Headquarter Location)
        1.3.1 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2018-2029)
        1.3.3 China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2018-2029)
        1.3.4 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2018-2029)
        1.3.5 Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2018-2029)
        1.3.6 South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2018-2029)
        1.3.7 ASEAN Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2018-2029)
        1.3.8 India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029)
    2.2 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region
        2.2.1 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region (2018-2023)
        2.2.2 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Forecast by Region (2024-2029)
    2.3 United States Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029)
    2.4 China Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029)
    2.5 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029)
    2.6 Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029)
    2.7 South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029)
    2.8 ASEAN Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029)
    2.9 India Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029)

3 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies Competitive Analysis
    3.1 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Chimeric Antigen Receptor (CAR) T-Cell Therapy in 2022
        3.2.3 Global Concentration Ratios (CR8) for Chimeric Antigen Receptor (CAR) T-Cell Therapy in 2022
    3.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Evaluation Quadrant
    3.4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Overall Company Footprint Analysis
        3.4.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Region Footprint
        3.4.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Type Footprint
        3.4.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Comparison
        4.2.1 United States VS China: Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies and Market Share, 2018-2023
        4.3.1 United States Based Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, (2018-2023)
    4.4 China Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Market Share, 2018-2023
        4.4.1 China Based Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, (2018-2023)
    4.5 Rest of World Based Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 CD19-targeted
        5.2.2 BCMA-targeted
    5.3 Market Segment by Type
        5.3.1 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2018-2023)
        5.3.2 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2024-2029)
        5.3.3 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Lymphoma
        6.2.2 Multiple Myeloma
    6.3 Market Segment by Application
        6.3.1 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2018-2023)
        6.3.2 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2024-2029)
        6.3.3 World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Novartis
        7.1.1 Novartis Details
        7.1.2 Novartis Major Business
        7.1.3 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.1.4 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Novartis Recent Developments/Updates
        7.1.6 Novartis Competitive Strengths & Weaknesses
    7.2 Gilead Sciences
        7.2.1 Gilead Sciences Details
        7.2.2 Gilead Sciences Major Business
        7.2.3 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.2.4 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Gilead Sciences Recent Developments/Updates
        7.2.6 Gilead Sciences Competitive Strengths & Weaknesses
    7.3 Bristol-Myers Squibb
        7.3.1 Bristol-Myers Squibb Details
        7.3.2 Bristol-Myers Squibb Major Business
        7.3.3 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.3.4 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Bristol-Myers Squibb Recent Developments/Updates
        7.3.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
    7.4 J & J
        7.4.1 J & J Details
        7.4.2 J & J Major Business
        7.4.3 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.4.4 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 J & J Recent Developments/Updates
        7.4.6 J & J Competitive Strengths & Weaknesses
    7.5 JW Therapeutics
        7.5.1 JW Therapeutics Details
        7.5.2 JW Therapeutics Major Business
        7.5.3 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.5.4 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 JW Therapeutics Recent Developments/Updates
        7.5.6 JW Therapeutics Competitive Strengths & Weaknesses
    7.6 FOSUNKite
        7.6.1 FOSUNKite Details
        7.6.2 FOSUNKite Major Business
        7.6.3 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.6.4 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 FOSUNKite Recent Developments/Updates
        7.6.6 FOSUNKite Competitive Strengths & Weaknesses
    7.7 CARsgen Therapeutics
        7.7.1 CARsgen Therapeutics Details
        7.7.2 CARsgen Therapeutics Major Business
        7.7.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.7.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 CARsgen Therapeutics Recent Developments/Updates
        7.7.6 CARsgen Therapeutics Competitive Strengths & Weaknesses
    7.8 Autolus Therapeutics
        7.8.1 Autolus Therapeutics Details
        7.8.2 Autolus Therapeutics Major Business
        7.8.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.8.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Autolus Therapeutics Recent Developments/Updates
        7.8.6 Autolus Therapeutics Competitive Strengths & Weaknesses
    7.9 Sorrento Therapeutics
        7.9.1 Sorrento Therapeutics Details
        7.9.2 Sorrento Therapeutics Major Business
        7.9.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.9.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Sorrento Therapeutics Recent Developments/Updates
        7.9.6 Sorrento Therapeutics Competitive Strengths & Weaknesses
    7.10 Mustang Bio
        7.10.1 Mustang Bio Details
        7.10.2 Mustang Bio Major Business
        7.10.3 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.10.4 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Mustang Bio Recent Developments/Updates
        7.10.6 Mustang Bio Competitive Strengths & Weaknesses
    7.11 Bluebird Bio
        7.11.1 Bluebird Bio Details
        7.11.2 Bluebird Bio Major Business
        7.11.3 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.11.4 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Bluebird Bio Recent Developments/Updates
        7.11.6 Bluebird Bio Competitive Strengths & Weaknesses
    7.12 Cellectis
        7.12.1 Cellectis Details
        7.12.2 Cellectis Major Business
        7.12.3 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.12.4 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.12.5 Cellectis Recent Developments/Updates
        7.12.6 Cellectis Competitive Strengths & Weaknesses
    7.13 Allogene Therapeutics
        7.13.1 Allogene Therapeutics Details
        7.13.2 Allogene Therapeutics Major Business
        7.13.3 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.13.4 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.13.5 Allogene Therapeutics Recent Developments/Updates
        7.13.6 Allogene Therapeutics Competitive Strengths & Weaknesses
    7.14 Celyad
        7.14.1 Celyad Details
        7.14.2 Celyad Major Business
        7.14.3 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
        7.14.4 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.14.5 Celyad Recent Developments/Updates
        7.14.6 Celyad Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Chain
    8.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Upstream Analysis
    8.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Midstream Analysis
    8.4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Chimeric Antigen Receptor (CAR) T-Cell Therapy Players in 2022
    Table 12. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Company Evaluation Quadrant
    Table 14. Head Office of Key Chimeric Antigen Receptor (CAR) T-Cell Therapy Player
    Table 15. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Type Footprint
    Table 16. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Application Footprint
    Table 17. Chimeric Antigen Receptor (CAR) T-Cell Therapy Mergers & Acquisitions Activity
    Table 18. United States VS China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share (2018-2023)
    Table 23. China Based Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Chimeric Antigen Receptor (CAR) T-Cell Therapy Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share (2018-2023)
    Table 29. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2024-2029) & (USD Million)
    Table 35. Novartis Basic Information, Area Served and Competitors
    Table 36. Novartis Major Business
    Table 37. Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 38. Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Novartis Recent Developments/Updates
    Table 40. Novartis Competitive Strengths & Weaknesses
    Table 41. Gilead Sciences Basic Information, Area Served and Competitors
    Table 42. Gilead Sciences Major Business
    Table 43. Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 44. Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Gilead Sciences Recent Developments/Updates
    Table 46. Gilead Sciences Competitive Strengths & Weaknesses
    Table 47. Bristol-Myers Squibb Basic Information, Area Served and Competitors
    Table 48. Bristol-Myers Squibb Major Business
    Table 49. Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 50. Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Bristol-Myers Squibb Recent Developments/Updates
    Table 52. Bristol-Myers Squibb Competitive Strengths & Weaknesses
    Table 53. J & J Basic Information, Area Served and Competitors
    Table 54. J & J Major Business
    Table 55. J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 56. J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. J & J Recent Developments/Updates
    Table 58. J & J Competitive Strengths & Weaknesses
    Table 59. JW Therapeutics Basic Information, Area Served and Competitors
    Table 60. JW Therapeutics Major Business
    Table 61. JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 62. JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. JW Therapeutics Recent Developments/Updates
    Table 64. JW Therapeutics Competitive Strengths & Weaknesses
    Table 65. FOSUNKite Basic Information, Area Served and Competitors
    Table 66. FOSUNKite Major Business
    Table 67. FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 68. FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. FOSUNKite Recent Developments/Updates
    Table 70. FOSUNKite Competitive Strengths & Weaknesses
    Table 71. CARsgen Therapeutics Basic Information, Area Served and Competitors
    Table 72. CARsgen Therapeutics Major Business
    Table 73. CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 74. CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. CARsgen Therapeutics Recent Developments/Updates
    Table 76. CARsgen Therapeutics Competitive Strengths & Weaknesses
    Table 77. Autolus Therapeutics Basic Information, Area Served and Competitors
    Table 78. Autolus Therapeutics Major Business
    Table 79. Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 80. Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Autolus Therapeutics Recent Developments/Updates
    Table 82. Autolus Therapeutics Competitive Strengths & Weaknesses
    Table 83. Sorrento Therapeutics Basic Information, Area Served and Competitors
    Table 84. Sorrento Therapeutics Major Business
    Table 85. Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 86. Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Sorrento Therapeutics Recent Developments/Updates
    Table 88. Sorrento Therapeutics Competitive Strengths & Weaknesses
    Table 89. Mustang Bio Basic Information, Area Served and Competitors
    Table 90. Mustang Bio Major Business
    Table 91. Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 92. Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. Mustang Bio Recent Developments/Updates
    Table 94. Mustang Bio Competitive Strengths & Weaknesses
    Table 95. Bluebird Bio Basic Information, Area Served and Competitors
    Table 96. Bluebird Bio Major Business
    Table 97. Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 98. Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 99. Bluebird Bio Recent Developments/Updates
    Table 100. Bluebird Bio Competitive Strengths & Weaknesses
    Table 101. Cellectis Basic Information, Area Served and Competitors
    Table 102. Cellectis Major Business
    Table 103. Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 104. Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 105. Cellectis Recent Developments/Updates
    Table 106. Cellectis Competitive Strengths & Weaknesses
    Table 107. Allogene Therapeutics Basic Information, Area Served and Competitors
    Table 108. Allogene Therapeutics Major Business
    Table 109. Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 110. Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 111. Allogene Therapeutics Recent Developments/Updates
    Table 112. Celyad Basic Information, Area Served and Competitors
    Table 113. Celyad Major Business
    Table 114. Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Services
    Table 115. Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 116. Global Key Players of Chimeric Antigen Receptor (CAR) T-Cell Therapy Upstream (Raw Materials)
    Table 117. Chimeric Antigen Receptor (CAR) T-Cell Therapy Typical Customers
List of Figure
    Figure 1. Chimeric Antigen Receptor (CAR) T-Cell Therapy Picture
    Figure 2. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (2018-2029) & (USD Million)
    Figure 13. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Chimeric Antigen Receptor (CAR) T-Cell Therapy by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Chimeric Antigen Receptor (CAR) T-Cell Therapy Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Chimeric Antigen Receptor (CAR) T-Cell Therapy Markets in 2022
    Figure 27. United States VS China: Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Market Share by Type in 2022
    Figure 31. CD19-targeted
    Figure 32. BCMA-targeted
    Figure 33. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Market Share by Type (2018-2029)
    Figure 34. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 35. World Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Market Share by Application in 2022
    Figure 36. Lymphoma
    Figure 37. Multiple Myeloma
    Figure 38. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industrial Chain
    Figure 39. Methodology
    Figure 40. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad

Related Reports

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 07 Aug 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size was valued at USD 2887.2 million in 2022 and is forecast to a readjusted size of USD 16370 million by 2029 with a CAGR of 28.1% during review period.

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 13 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size was valued at USD 2887.2 million in 2023 and is forecast to a readjusted size of USD 16370 million by 2030 with a CAGR of 28.1% during review period.

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Supply, Demand and Key Producers, 2024-2030

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Supply, Demand and Key Producers, 2024-2030

date 16 Feb 2024

date Pharma & Healthcare

The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size is expected to reach $ 16370 million by 2030, rising at a market growth of 28.1% CAGR during the forecast period (2024-2030).

Product Tags

Chimeric Antigen Receptor (CAR) T-Cell Therapy

Chimeric Antigen Receptor (CAR)-T Cell Therapy

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>